Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Schizophrenia Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (First Generation Drugs, Second Generation Drugs, Third Generation Drugs)
5.2.2. By Route Of Administration (Injectable, Oral)
5.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
5.2.4. By Company (2022)
5.3. Market Map
5.3.1 By Drug Class
5.3.2 By Route of Administration
5.3.3 By Region
6. North America Schizophrenia Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class (First Generation Drugs, Second Generation Drugs, Third Generation Drugs)
6.2.2. By Route Of Administration (Injectable, Oral)
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Schizophrenia Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Route of Administration
6.3.2. Canada Schizophrenia Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Route of Administration
6.3.3. Mexico Schizophrenia Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Route of Administration
7. Europe Schizophrenia Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class (First Generation Drugs, Second Generation Drugs, Third Generation Drugs)
7.2.2. By Route Of Administration (Injectable, Oral)
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Schizophrenia Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Route of Administration
7.3.2. Germany Schizophrenia Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Route of Administration
7.3.3. United Kingdom Schizophrenia Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Route of Administration
7.3.4. Italy Schizophrenia Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Route of Administration
7.3.5. Spain Schizophrenia Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Route of Administration
8. Asia-Pacific Schizophrenia Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class (First Generation Drugs, Second Generation Drugs, Third Generation Drugs)
8.2.2. By Route Of Administration (Injectable, Oral)
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Schizophrenia Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Route of Administration
8.3.2. India Schizophrenia Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Route of Administration
8.3.3. Japan Schizophrenia Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Route of Administration
8.3.4. South Korea Schizophrenia Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Route of Administration
8.3.5. Australia Schizophrenia Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Route of Administration
9. South America Schizophrenia Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class (First Generation Drugs, Second Generation Drugs, Third Generation Drugs)
9.2.2. By Route Of Administration (Injectable, Oral)
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Schizophrenia Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Route of Administration
9.3.2. Argentina Schizophrenia Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Route of Administration
9.3.3. Colombia Schizophrenia Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Route of Administration
10. Middle East and Africa Schizophrenia Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class (First Generation Drugs, Second Generation Drugs, Third Generation Drugs)
10.2.2. By Route Of Administration (Injectable, Oral)
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Schizophrenia Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Route of Administration
10.3.2. Saudi Arabia Schizophrenia Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Route of Administration
10.3.3. UAE Schizophrenia Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Route of Administration
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Global Schizophrenia Drugs Market: SWOT Analysis
14. Porter?s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Alkermes Plc
15.1.1. Business Overview
15.1.2. Product Offerings
15.1.3. Recent Developments
15.1.4. Financials (As Reported)
15.1.5. Key Personnel
15.1.6. SWOT Analysis
15.2. Eli Lilly and Company.
15.3. Johnson & Johnson.
15.4. AstraZeneca.
15.5. Pfizer Inc.
15.6. AbbVie Inc.
15.7. Otsuka Pharmaceutical Inc.
15.8. Bristol-Myers Squibb Company.
15.9. Sumitomo Dainippon Pharma.
15.10. Acadia Pharmaceuticals.
16. Strategic Recommendations